Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer252
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions129
Regulation of dormancy during tumor dissemination: the role of the ECM115
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities106
The functions and modifications of tRNA-derived small RNAs in cancer biology82
Clonal tracking in cancer and metastasis82
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression79
Obesity and cancer73
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective61
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms58
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?54
CAR T-cell therapy to treat multiple myeloma: current state and future directions53
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations53
Targeting lipid metabolism in cancer: neuroblastoma52
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor51
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer50
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond47
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review44
p73 isoforms meet evolution of metastasis42
Cell-cell interactions mediating primary and metastatic breast cancer dormancy41
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?40
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives39
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients38
Biography—Mathieu Boissan, Pharm.D., Ph.D37
Preface36
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance33
Neuropeptide Y in cancer—biological functions and potential clinical implications32
Biographies32
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications31
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance30
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis29
The role of cancer cell bioenergetics in dormancy and drug resistance29
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy28
Clusterin: a marker and mediator of chemoresistance in colorectal cancer28
Short-chain fatty acids in cancer pathogenesis28
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development27
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy27
Carcinoma of unknown primary (CUP): an update for histopathologists26
Functional and clinical roles of stromal PDGF receptors in tumor biology26
Tumor necrosis factor superfamily signaling: life and death in cancer26
The emerging roles of histone demethylases in cancers26
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions26
Clinical interventions to break the obesity and cancer link: a narrative review26
Vaping and tumor metastasis: current insights and progress26
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape25
Inflammatory bowel disease and carcinogenesis25
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy25
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution25
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review25
Kenneth V. Honn, Ph.D. (1946–2023)25
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy25
OX40/OX40 ligand and its role in precision immune oncology25
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting24
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies23
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect23
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases23
HOXA9 transcription factor is a double-edged sword: from development to cancer progression23
New progress of tuberculosis scar carcinoma22
Biographies22
Ferroptosis: iron release mechanisms in the bioenergetic process22
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases21
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX21
0.10964179039001